BioRestorative Therapies

116 articles with BioRestorative Therapies

• BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

  11/10/2021

  BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced that it has appointed Robert Kristal to the position of Chief Financial Officer.

• BioRestorative Therapies Announces Closing of $23 Million Public Offering

  11/9/2021

  BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced the closing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00.

• BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market

  11/5/2021

  BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced the pricing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00.

• BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors

  10/26/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the nomination of two new independent members to its Board of Directors with industry and medical device experience: Patrick F. Williams, Chief Financial Officer at STAAR Surgical, and David Rosa, President and Chief Executive Officer at NeuroOne.

• BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

  10/26/2021

  BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced its intention to effect a 1-for-4,000 reverse split of its common stock in preparation for the planned listing of the Company’s securities on The Nasdaq Capital Market.

• BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program

  9/23/2021

  BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance for a patent application for its metabolic ThermoStem® program. 

• BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program

  9/2/2021

  BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australian Patent Office has issued the Company a patent related to its metabolic ThermoStem® Program.

• BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program

  8/31/2021

  BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued the Company a patent related to its metabolic ThermoStem® Program.

• BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook

  8/19/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has been named one of the Top 10 Spine Device Companies and featured by MedTech Outlook, a leading print and digital magazine that provides details and insights regarding novel and high impact medical technologies.

• BioRestorative Therapies Discusses Upcoming Annual Meeting of Stockholders

  8/11/2021

  BioRestorative Therapies, Inc. today reminded its stockholders that its annual meeting of stockholders will be held on Tuesday, August 17, 2021 at 10 a.m. EDT.

• BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering

  8/9/2021

  BioRestorative Therapies, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed underwritten public offering of its securities.

• BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021

  6/7/2021

  BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference.

• BioRestorative Therapies Expanding its Cell Therapy Manufacturing Facility

  5/10/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it is initiating expansion of its Melville, New York based research laboratories to include capabilities for the clinical production of the Company’s pipeline of clinical and investigational cell therapy candidates.

• BioRestorative Therapies Announces Compliance with SEC Reporting Requirements and “Stop Sign” Removal

  5/3/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings.

• BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors

  4/5/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the appointment of Nickolay V. Kukekov to the BioRestorative Board of Directors, effective March 18th, 2021.

• BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem® ProgramNotice of Allowance Grants Protection for Deriving Exosomes from Brown Adipocytes

  3/31/2021

  BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX) , a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem ® Program. The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.

• BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem® Program

  3/22/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that the United States Patent Office and several International agencies have issued notices of allowance for three separate patent applications related to the Company’s metabolic ThermoStem® Program.

• BioRestorative Therapies Announces Filing of 2019 Annual Report on Form 10-K

  3/18/2021

  BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on BioRestorative Therapies website, www.biorestorative.com, by selecting “Investors” and then “SEC Filings”.

• BioRestorative Therapies Provides End of Year Shareholder LetterCompany Expects Several Milestones as Momentum Builds for 2021

  1/5/2021

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the following letter from its Chief Executive Officer, Lance Alstodt, to its shareholders and the investment community.

• BioRestorative Therapies Emerges from Chapter 11 Reorganization

  11/20/2020

  BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that its amended joint plan of reorganization has become effective and it has emerged from Chapter 11 reorganization.